Search Results

You are looking at 1 - 10 of 16 items for :

  • "iron chelation" x
Clear All
Full access

David P. Steensma

chelation therapy among patients with iron overload in MDS Identify adverse events associated with oral iron chelation therapy M ore than 90% of patients with myelodysplastic syndromes (MDS) are anemic at the time of diagnosis, 1 and most patients will

Full access

Peter L. Greenberg

transfusional iron overload in adults . N Engl J Med 1981 ; 304 : 319 – 324 . 5. Jaeger M Aul C Sohngen D . Iron overload in polytransfused patients with MDS: the use of L1 for oral iron chelation . Drugs Today 1992 ; 28 [ suppl A ]: 143 – 147

Full access

Peter L. Greenberg, Cynthia K. Rigsby, Richard M. Stone, H. Joachim Deeg, Steven D. Gore, Michael M. Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Paul J. Shami and Rashmi Kumar

; 2 : 27 – 30 . 4 Hershko CM Link GM Konijn AM Cabantchik ZI . Iron chelation therapy . Curr Hematol Rep 2005 ; 4 : 110 – 116 . 5 Olivieri NF Brittenham GM . Iron-chelating therapy and the treatment of thalassemia . Blood

Full access

Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro and Gary H. Lyman

granulocyte colony-stimulating factor in combination with erythropoietin . Blood 1993 ; 82 : 737 – 743 . 7. Gotlib J Greenberg PL . Supportive care in myelodysplastic syndromes: hemopoietic cytokine and iron chelation therapy . In: Greenberg PL

Full access

Now Available Online: NCCN Task Force: Transfusion and Iron Overload in Patients With Myelodysplastic Syndromes In October 2009, NCCN convened a multidisciplinary task force to critically review the evidence for iron chelation and the

Full access

Role of Iron Chelation Therapy for Patients With Myelodysplastic Syndromes Steensma David P. MD 1 2011 9 9 1 1 65 65 75 75 jnccn0090065 10.6004/jnccn.2011.0007 Epithelial Ovarian Cancer Morgan Robert J. Jr. MD Alvarez Ronald D. MD

Full access

Jesse D. Troy, Carlos M. de Castro, Mary Ruth Pupa, Greg P. Samsa, Amy P. Abernethy and Thomas W. LeBlanc

agent, lenalidomide, growth factors, iron chelation, transfusions, other chemotherapy [eg, induction therapy], and HSCT), blood counts, participation in a clinical trial, and progression to acute myeloid leukemia (AML). Vital status was determined

Full access

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, James M. Foran, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Mark A. Schroeder, Paul J. Shami, Richard M. Stone, James E. Thompson and Peter Westervelt

overload states (e.g., thalassemia) using iron chelation therapy has been shown in patients in whom the most effective chelation occurred. 43 , 47 This included transfusion independence in a portion of a small group of carefully studied patients with MDS

Full access

Peter L. Greenberg, Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Virginia Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O’Donnell, Daniel A. Pollyea, Bart Scott, Paul J. Shami, Brady L. Stein, Peter Westervelt, Benton Wheeler, Dorothy A. Shead and Courtney Smith

deposition in the liver, heart, skin, and endocrine organs, resulting in potential complications and the need to consider iron chelation medications to prevent or stabilize such adverse events (see MDS-B, page 267). The standard method to attempt to

Full access

H. Joachim Deeg and Marcos de Lima

have shown that iron overload, associated with the MDS disease process itself or related to red blood cell transfusions, negatively impacts transplant outcome, and iron chelation might attenuate that effect. 19 - 21 In principle, however, adjustment of